Resmiterom Efficacy & Safety in Patients With MASH

Recruiting now · Phase 4

Conditions studied: MASH - Metabolic Dysfunction-Associated Steatohepatitis

In brief

Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.

Key facts

Study ID

NCT07249788

Run by

Nabiqasim Industries (Pvt) Ltd

People needed

165

Starts

2025-10-17

Expected to finish

2026-12-31

Last updated by the study team

2025-12-03

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension)
• Clinical diagnosis of MASH using:
• LSM ≥ 8.5kpa And/or
• FAST score ≥0.67 And/or
• FibroScan CAP ≥ 275 dB/m And/or
• FIB-4 > 1.3

You may not qualify if…

• • History of drug addiction and alcoholism
• Cirrhosis or decompensated liver disease
• Chronic viral hepatitis HBV, HCV)
• MACE including MI, Stroke, PE etc.
• Pregnant/lactating women
• Concurrent use of other investigational drugs
• History of other liver diseases (viral, autoimmune, drug-induced, alcohol)
• Previous use of resmetirom in last 6 months
• Significant renal impairment (eGFR <30)

Where it is running

• Liver transplant center, Holy family hospital — Rawalpindi, Punjab Province, Pakistan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.